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Background. Lung transplant recipients are frequently exposed to respiratory viruses and are particularly at
risk for severe complications. The aim of this study was to assess the association among the presence of a respiratory
virus detected by molecular assays in bronchoalveolar lavage (BAL) fluid, respiratory symptoms, and acute rejection
in adult lung transplant recipients.
Methods. Upper (nasopharyngeal swab) and lower (BAL) respiratory tract specimens from 77 lung transplant
recipients enrolled in a cohort study and undergoing bronchoscopy with BAL and transbronchial biopsies were
screened using 17 different polymerase chain reaction–based assays.
Results. BAL fluid and biopsy specimens from 343 bronchoscopic procedures performed in 77 patients were
analyzed. We also compared paired nasopharyngeal and BAL fluid specimens collected in a subgroup of 283 cases.
The overall viral positivity rate was 29.3% in the upper respiratory tract specimens and 17.2% in the BAL samples
( ). We observed a significant association between the presence of respiratory symptoms and positive viralP ! .001
detection in the lower respiratory tract ( ). Conversely, acute rejection was not associated with the presencePp .012
of viral infection (odds ratio, 0.41; 95% confidence interval, 0.20–0.88). The recovery of lung function was
significantly slower when acute rejection and viral infection were both present.
Conclusions. A temporal relationship exists between acute respiratory symptoms and positive viral nucleic
acid detection in BAL fluid from lung transplant recipients. We provide evidence suggesting that respiratory viruses
are not associated with acute graft rejection during the acute phase of infection.
Lung transplant recipients are exposed to respiratory
viruses circulating year-round in the community [1–
6]. In the general population, most of these infections
lead to self-limited upper respiratory tract diseases, but
protracted respiratory viral infection and lower respi-
ratory tract complications are more likely in lung trans-
plant recipients. This is related to specific risk factors,
including direct exposure of the graft to airborne vi-
ruses, impaired mucociliary clearance, poor cough re-
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flex, and abnormal lymphatic drainage. Nevertheless,
our knowledge of the clinical effect of respiratory vi-
ruses is incomplete, particularly when detected by mo-
lecular assays applied to lower respiratory tract speci-
mens. This is in part due to the retrospective design of
most available studies, the use of different sampling
sites (upper vs lower respiratory tract specimens), and
the heterogeneity of diagnostic procedures (conven-
tional vs molecular techniques) [1, 2, 4, 6–13].
In addition to the direct consequences of any viral
infection, subsequent cellular injury and altered host
immunity could also initiate a cascade of immunologic
events [14–16], leading to acute and chronic allograft
rejection. Although several studies support the associ-
ation between respiratory viruses and chronic lung re-
jection [1, 3, 10, 12, 14, 17–19], the link between res-
piratory viruses and acute rejection has been studied
mainly in small case series or by subgroup analysis [1,
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2, 9–11, 20, 21]. On the basis of available evidence, the rela-
tionship between viral infection and acute rejection has not
been established.
The present investigation was specifically designed to assess
the epidemiology of respiratory viruses in bronchoalveolar lav-
age (BAL) fluid from lung transplant recipients and to analyze
the relationship between these viruses and the presence of acute
graft rejection. The most sensitive molecular assay methods
were used to identify as many as 17 common respiratory viruses
in not only the lower but also the upper respiratory tract.
Symptoms were carefully and prospectively described, and their
association with either respiratory viruses or acute rejection
was analyzed.
METHODS
Study population and procedures. During a 27-month study
period from November 2003 through March 2006 (covering 3
winter seasons), lung transplant recipients were enrolled in a
prospective cohort study [22]. Patients were followed up at the
2 sites of a single transplantation network, including the Uni-
versity Hospitals of Geneva (Geneva, Switzerland) and the Uni-
versity Hospital of Lausanne (Lausanne, Switzerland).
Informed consent was required from each participant, and
the study was approved by both institutional ethics committees.
Any lung transplant recipient who underwent bronchoscopy
with BAL and transbronchial biopsies was eligible, irrespective
of the reasons leading to the procedure. On the basis of stan-
dardized guidelines, we perform routinely scheduled bron-
choscopies at 1, 3, 6, and 12 months after transplantation and
yearly thereafter. Other indications for bronchoscopy with
transbronchial biopsies include unexplained respiratory symp-
toms, functional deterioration with a 12% decrease in the
forced expiratory volume in 1 s (FEV1), new chest radiologic
infiltrate, and control procedure 1 month after treatment of
any rejection of grade A3 or higher. Thus, patients could un-
dergo bronchoscopy for a variety of reasons with additional
procedures during the study period. For technical reasons (eg,
pathologist availability), transbronchial biopsies are not per-
formed during weekends and holidays at our centers. For safe-
ty and ethical reasons, no additional bronchoscopy was per-
formed only for the purpose of the study.
The BAL procedure and the real-time TaqMan reverse-tran-
scription polymerase chain reaction (RT-PCR) assays for the
detection of RNA respiratory viruses (influenza viruses A, B,
and C; respiratory syncytial viruses A and B; parainfluenza
viruses 1, 2, 3, and 4; human rhinovirus; enterovirus; human
metapneumovirus; and coronaviruses OC43, 229E, NL63, and
HKU1) were performed as described elsewhere [22–24]. The
recently identified bocavirus was added. Transbronchial biop-
sies were performed under fluoroscopic guidance using stan-
dard procedures [25] and analyzed according to published
guidelines [26] by senior pathologists masked to the viral re-
sults. Pooled nasopharyngeal and oropharyngeal swab speci-
mens were obtained from patients who agreed to the procedure.
For technical reasons and reasons of cost (110,500 RT-PCR
assays were performed), the procedure (nasopharyngeal and
oropharyngeal swabbing) was limited to 80% of the cases se-
lected during the entire study period. Swabs were immediately
placed on appropriate transport medium and stored at 80C
until further RT-PCR analysis. Shortly before each broncho-
scopic procedure, a specific case report form was completed
and symptoms, reasons leading to the BAL procedure, and the
presumed diagnosis based on the available clinical data at the
time were recorded. Rhinopharyngitis was defined as the pres-
ence of acute respiratory symptoms with at least acute rhi-
norrhea with or without additional signs suggesting acute si-
nusitis and/or acute pharyngitis (sore throat confirmed by the
presence of inflammatory signs on clinical examination). Flu-
like illness was defined as the presence of a temperature 137.8C
plus 2 of the following 4 symptoms: cough, myalgia, sore throat,
or headache. When available, lung functions measured 2–6
weeks before, at the time of, and 2–6 weeks after the BAL
procedure were recorded. FEV1 and maximal midexpiratory
flow of 25%–75% were also recorded. Impaired lung function
was defined as a 12% decrease from the previous value.
Statistical analysis. Each episode was classified into 4 cat-
egories according to the respective absence (A0 or A1 grade)
or presence (A2, A3, or A4 grade) of acute rejection and/or
respiratory virus. We considered only acute rejection grade A2
or higher in the analysis, because most centers would not rec-
ommend high-dose immunosuppressive treatment for a lower
acute rejection grade. The Fisher exact test was used to compare
the frequency of respiratory symptoms in each category. Gen-
eralized linear latent and mixed models (Stata software, version
10; StataCorp) were used for analysis of lung functions at each
episode to take into account the repeated measures in each
patient at the 2 study sites. Odds ratios (ORs) for acute rejection
associated with respiratory viruses were calculated using the
same statistical approach for repeated measures. To investigate
a potential time-specific relationship between respiratory vi-
ruses and acute rejection, we repeated our analyses of episodes
restricted to 4 key periods: 0–3 months, 4–6 months, 7–12
months, and 112 months after lung transplantation.
RESULTS
Population and indications for bronchoscopy. Seventy-seven
lung transplant recipients underwent 343 bronchoscopies. Pa-
tient characteristics are given in Table 1. All patients received
induction immunosuppression with anti–interleukin 2 receptor
antibodies (basiliximab) postoperatively, followed by a triple
immunosuppression regimen of calcineurin or target of rapa-
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Table 1. Patient Characteristics (n p 77)
Characteristic Value
Age at lung transplantation, years
Median (IQR) 48.6 (27.3)
Range 7–66
Male 43 (55.8)
Type of transplantation
Single lung transplantation 12 (15.6)
Double lung transplantation 65 (84.4)
Baseline condition
Chronic obstructive pulmonary disease 37 (48.1)
Cystic fibrosis 22 (28.6)
Idiopathic pulmonary fibrosis 6 (10.4)
Pulmonary hypertension 3 (3.9)
Other 9 (11.7)
Bronchoscopic procedures, median no. per patient (range) 4 (1–23)
NOTE. Data are no. (%) of patients, unless otherwise indicated. IQR, interquartile
range.
Table 2. Type and Number of Respiratory Viruses Detected in
Bronchoalveolar Lavage (BAL) Fluid Specimens
Variable Value
Total no. of analyzed BAL fluid specimens 343
Virus-negative BAL fluid specimens 284 (82.8)
Virus-positive BAL fluid specimens 59 (17.2)a
Total no. of identified viruses 63
Type of identified viruses
Rhinovirus 22 (37.3)
Coronavirusesb 17 (28.8)
Parainfluenza virusesc 13 (22.0)
Respiratory syncytial virusesd 7 (11.9)
Human metapneumovirus 3 (5.1)
Influenza virusese 1 (1.7)
Enterovirus 0 (0)
NOTE. Data are no. (%), unless otherwise indicated.
a Dual infection in 4 cases.
b Coronavirus 229E, OC43, NL63, or HKU1.
c Parainfluenza virus 1, 2, or 3.
d Respiratory syncytial virus A or B.
e Influenza virus A, B, or C.
mycin inhibitors, azathioprine or mycophenolate mofetil, and
prednisone.
Of the 343 bronchoscopies, 229 (66.8%) were performed as
routinely scheduled procedures, 85 (24.8%) were performed
for a new clinical condition, and 29 (8.5%) were performed as
a control biopsy after treatment for an acute rejection (grade
A3 or higher) episode. Some patients included for a routinely
scheduled bronchoscopy presented with a new respiratory
symptom with or without functional impairment and/or new
radiologic infiltrate. Taken together, 224 (65.3%) of 343 cases
had at least 1 new respiratory symptom, and 54 (15.7%) had
a new radiologic infiltrate. On the basis of the pretest evalua-
tion, acute lung rejection and infection were suspected by the
physician in charge, who was masked to microbiological results,
in 176 cases (51.3%) and 99 cases (28.9%), respectively. For
the remaining 68 cases (19.8%), the clinician did not suspect
any particular diagnosis.
RT-PCR assays. The RT-PCR viral assays performed on
the 343 BAL fluid specimens revealed an overall positivity rate
of 17.2% ( ). Eight BAL specimens were discarded be-np 59
cause they had thawed during an electricity power outage. Rhi-
novirus was the most frequently encountered virus, followed
by coronaviruses and parainfluenza viruses (Table 2). The viral
positivity rate for the 283 pooled nasopharyngeal and oro-
pharyngeal specimens tested (82.5% of the total study popu-
lation) was 29.3% ( ). The agreement between upper andnp 84
lower respiratory tract specimens according to each type of
viral genus is shown in Figure 1. Although influenza viruses,
human metapneumovirus, and bocavirus were mostly (or even
exclusively for bocavirus) found in the upper airway samples,
other viruses (rhinoviruses and respiratory syncytial viruses)
were found equally in the upper and lower respiratory tracts.
No virus was exclusively found in the lower airways.
Association between clinical suspicion and final diagnosis.
Because BAL fluid specimens were collected for a variety of
clinical conditions, we were able to analyze the association
among symptoms, the diagnosis suspected by the physician in
charge, and the subsequent presence of a proven upper and/
or lower respiratory tract viral infection. We found a significant
association between positive viral nucleic acid detection in BAL
fluid and the presence of at least 1 new respiratory symptom
( ), in particular cough ( ) and sputum pro-Pp .012 Pp .001
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Figure 1. Agreement between upper and lower respiratory tract reverse-transcription polymerase chain reaction results. Of 283 samples simultaneously
obtained from the upper (nasopharyngeal and oropharyngeal [NP]) and lower (bronchoalveolar lavage [BAL]) respiratory tract, 184 harbored no virus
and 99 were positive for at least 1 respiratory virus at at least 1 site. The total number of identified respiratory viruses was 107. This figure shows
their detailed distribution.
Table 3. Clinical Findings in the Upper and Lower Respiratory Tracts According to Viral Reverse-Transcription
Polymerase Chain Reaction Results (n p 283)
Variable
NP negative and
BAL negative
NP positive and
BAL negative
NP negative and
BAL positive
NP positive and
BAL positive P a
No. (%) of cases 185 (65.4) 51 (18.0) 14 (4.9) 33 (11.7)
Clinical findings
Fever (temperature, 37.5C) 11.9 9.8 7.1 18.2 .694
Rhinopharyngitis 11.4 21.6 7.1 27.3 .037
Flulike illness 7.6 17.6 21.4 21.2 .016
Cough 25.9 31.4 35.7 66.6 !.001
Sputum 15.1 27.4 14.3 48.5 !.001
Dyspnea 29.7 15.7 42.9 36.4 .080
FEV1 decrease of 12% 20.5 21.6 21.4 48.5 .057
New radiologic infiltrate 15.1 11.8 0.0 18.2 .417
1 symptom 60.5 60.8 85.7 84.8 .012
No symptoms 39.5 39.2 14.3 15.2 .012
Suspicion of infection 24.3 23.5 50.0 39.4 .070
NOTE. Data are percentage of cases, unless otherwise indicated. BAL, bronchoalveolar lavage; FEV1, forced expiratory volume in 1 s;
NP, pooled nasopharyngeal and oropharyngeal swabs.
a Calculated using the Fisher exact test.
duction ( ). Table 3 gives the clinical findings associatedPp .04
with virus positivity for upper and lower tract specimens. Phy-
sicians in charge suspected an infection in 20 (42.6%) of the
47 cases with virus-positive BAL fluid, compared with 57
(24.2%) of the 236 cases that were virus negative. A history of
rhinopharyngitis was documented in 20 (23.8%) of 84 cases
with a virus-positive nasopharyngeal swab specimen, compared
with 22 (11.1%) of 199 of those that were negative.
Acute rejection grade, lung function, and viral infection.
Of 343 biopsy specimens, 149 (43.4%) showed no evidence of
acute rejection, 78 (22.7%) revealed minimal (A1) rejection,
and 116 (33.8%) were graded A2 or higher. Similar to the
analysis given in Table 3, we first tested the accuracy of the
pretest clinical evaluation performed by the physician in charge.
When acute rejection was suspected by the clinician in charge,
this was histologically confirmed in 64.1% of cases in the ab-
sence of respiratory virus and in 84.6% of cases when a res-
piratory virus was simultaneously identified in BAL fluid (Table
4). Consistent with the results shown in Table 3, the presence
of any respiratory symptoms, cough, or sputum was signifi-
cantly associated ( for all) with the presence of a viralP ! .004
infection in BAL fluid, irrespective of the presence or absence
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Table 4. Clinical Findings According to the Presence of Acute Rejection (AR) and/or Respiratory Virus
in the Lower Respiratory Tract (n p 343)
Variable
Virus negative
and no AR
Virus negative
and AR
Virus positive
and no AR
Virus positive
and AR P a
No. (%) of cases 181 (52.8) 103 (30.0) 46 (13.4) 13 (3.8)
Clinical findings
Fever (temperature, 37.5C) 14.4 10.7 21.7 7.7 .322
Rhinopharyngitis 12.2 15.5 21.7 23.1 .320
Flulike illness 8.8 9.7 19.6 7.7 .195
Cough 30.9 26.2 56.5 53.8 .001
Sputum 20.4 16.5 39.1 46.2 .004
Dyspnea 30.9 28.2 41.3 38.5 .415
New radiologic infiltrate 16.6 14.6 13.0 23.1 .812
1 symptom 59.1 64.1 84.8 92.3 .001
No symptom 40.9 35.9 15.2 7.7 .001
Suspicion of infection 28.2 22.3 45.6 30.8 .036
Suspicion of AR 40.3 64.1 56.5 84.6 !.001
NOTE. Data are percentage of cases, unless otherwise indicated.
a Calculated using the Fisher exact test.
Figure 2. Lung function evolution according to the presence of acute rejection (AR) and/or positive viral nucleic acid detection in bronchoalveolar
lavage fluid. Results are expressed at each time point as mean forced expiratory volume in 1 s (FEV1) values  standard errors, in liters. The FEV1
values for the 3 time points were available for 251 (73.2%) of 343 cases. T  (2–6) weeks, FEV1 baseline value measured 2–6 weeks before the
event leading to bronchoscopy; T0, FEV1 measured immediately before bronchoscopy; T + (2–6) weeks, FEV1 value measured 2–6 weeks after bronchoscopy.
* .P ! .05
of acute rejection. Impairment of lung function related to acute
rejection was also significantly worsened by the presence of a
viral infection (Figure 2). In patients with simultaneous acute
rejection and lower respiratory tract viral infection, the FEV1
recovery rate was significantly slower than in patients who had
acute rejection without simultaneous viral infection ( ).P ! .05
We found that the OR for acute rejection was !1 in the presence
of a viral infection for each of the 4 periods studied (OR for
any period, 0.41; 95% confidence interval [CI], 0.20–0.88). The
overall rate of viral infection in grade A0 and A1 cases was
25.4% (46 of 181), compared with 12.6% (13 of 103) in grade
A2 or higher. Thus, patients with a lower acute rejection grade
were twice as likely to be positive for viral infection than those
with a higher rejection grade (OR, 2.0; 95% CI, 1.04–3.9). When
repeating these analyses with the presence of virus in the upper
respiratory tract as a predictor of acute rejection, we did not
find an association between upper respiratory tract viral infec-
tion and acute rejection (OR, 1.11; 95% CI, 0.6–2.05). In a
supplementary analysis, we verified the occurrence of acute re-
jection during a 30-day and 90-day period after baseline bron-
choscopy. At 30 and 90 days, the probability of acute rejection
was associated with the presence of acute rejection at baseline
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Table 5. Acute Rejection (AR) Rate 30 and 90 Days after Bron-
choscopic Procedure According to the Presence of AR and/or
Respiratory Virus in the Lower Respiratory Tract (Bronchoalveolar
Lavage [BAL] Fluid)
Variable
AR rate,
proportion (%) P a
Rate at 30 days (n p 75) .683
Virus negative
AR positive 14/24 (58.3)
AR negative 7/30 (23.3)
Virus positive
AR positive 3/6 (50.0)
AR negative 5/15 (33.3)
Rate at 90 days (n p 185) .558
Virus negative
AR positive 32/78 (41.0)
AR negative 18/72 (25.0)
Virus positive
AR positive 6/12 (50.0)
AR negative 7/23 (30.4)
NOTE. The table includes 75 episodes for which a bronchoscopic proce-
dure was performed within a 30-day period and 185 episodes for which a
procedure was performed within a 90-day period. Patients with virus-positive
BAL samples were as likely to be given diagnoses of AR at 30 and 90 days
(odds ratio for 30 days, 1.22; 95% confidence interval, 0.46–3.24; odds ratio
for 90 days, 1.30; 95% confidence interval, 0.62–2.69).
a Calculated using the Fisher exact test.
but not with the presence of virus (OR for 30 days, 1.22; 95%
CI, 0.46–3.24; OR for 90 days, 1.30; 95% CI, 0.62–2.69) (Ta-
ble 5).
DISCUSSION
Using an extensive panel of molecular assays, we were able to
show that 17.2% of prospectively collected BAL fluid specimens
from adult lung transplant recipients were positive for at least
1 respiratory virus. On the basis of a pretest clinical evaluation,
patients testing positive were significantly more likely to present
with respiratory symptoms (86.4%, compared with 60.9% with
no identified virus). All analyzed individual symptoms were
systematically more frequent in the presence of a respiratory
virus, particularly cough and sputum, which were up to 3 times
more common. Consistent with these observations, the pretest
clinical evaluation performed by the physicians in charge con-
sidered that an infection was more likely in those with a final
positive viral detection. Furthermore, lung function proved to
recover significantly slower in the presence of a respiratory
virus. All these findings corroborate that a positive association
exists between positive viral nucleic acid detection in BAL fluid
and the presence of an acute respiratory illness in lung trans-
plant patients. This is also concordant with other investigations
that have linked the detection of respiratory viruses by RT-PCR
to symptoms [1, 2, 4, 6, 10, 13, 27]. However, our investigation
differs from these studies by its prospective design, the large
panel of respiratory viruses screened, the systematic use of BAL
specimens, and the integration of pretest clinical evaluations
performed by the physicians in charge. Many of the previous
studies limited the detection strategy to upper respiratory tract
specimens and used an array of molecular tools that was often
restricted to a subgroup of viruses (eg, rhinoviruses, corona-
viruses, or bocaviruses were not systematically tested). Finally,
the link with pretest clinical conditions was not detailed in
many of these reports.
Because of the availability of lung biopsy specimens in all
cases, we were also able to assess the presence of acute rejection
according to the presence of viral infection. A relationship be-
tween acute viral infection and subsequent acute rejection has
been reported in small case series, but this possible association
has not been appropriately confirmed. Viral infection might
trigger a chain of immunologically mediated events, leading to
subsequent rejection or lung dysfunction. This is important
because several studies have identified viral infection as a dis-
tinct risk factor for the development of bronchiolitis obliterans
syndrome and chronic graft dysfunction [1, 3, 4, 10, 12, 14,
17, 18]. Our investigation had the capacity to address this ques-
tion because we were able to analyze a high number of lung
biopsy specimens together with viral screening at the level of
the lower respiratory tract. The biopsy analysis revealed that
viral respiratory tract infections were not associated with si-
multaneous acute rejection. Furthermore, we could show that
the probability of acute rejection did not increase 30 and 90
days after a lower airways respiratory viral infection. When
present, however, viral infections caused more severe lung dys-
function and significantly hampered the short-term functional
recovery in the case of concomitant acute rejection. Because
the clinician in charge was masked to any viral result, a positive
RT-PCR result did not modify the treatment of simultaneous
acute rejection. Thus, a less aggressive treatment of acute re-
jection in the presence of a virus cannot explain the slower
recovery of lung function in these patients. This suggests that
respiratory viruses per se do not promote acute rejection during
the acute phase but could certainly worsen lung function and
impair recovery from acute rejection episodes. Paradoxically,
we even observed a negative association between an episode of
respiratory viral infection and the subsequent cumulative risk
of developing acute rejection. This should not be considered a
protective effect of viral infections; more likely, it is a lack of
an association or a chance effect, and we refrain from drawing
any other conclusions. However, this strongly suggests that when
analyzing biopsy specimens according to reference guidelines
[26], pathologists should not be misguided by the presence of a
viral infection.
Of note, our study design limited follow-up to a few weeks,
and we cannot exclude the possibility that the viral infection
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triggered a chain of immunologically mediated events, leading
to subsequent rejection or lung dysfunction. This is important
because several studies have identified viral infection as a dis-
tinct risk factor for the development of bronchiolitis obliterans
syndrome and chronic graft dysfunction [1, 3, 4, 10, 12, 14,
17, 18].
Our investigation also provided the unique opportunity to
compare viral detection in the upper (pooled nasopharyngeal
and oropharyngeal swabs) and lower respiratory tract in a large
number of paired specimens. The positivity rate in the upper
respiratory tract was 29.6%, compared with 16.6% in the lower
tract. This difference in recovery rate is similar to that observed
in other smaller studies [12], but, to the best of our knowledge,
few or none of the previous investigations systematically ana-
lyzed paired specimens collected during the same procedure.
An important observation is that when recovered only in the
upper respiratory tract, respiratory viruses were less likely to
be associated with lower respiratory symptoms. Another in-
teresting observation is that only 7.0% of negative nasopha-
ryngeal specimens were associated with a discordant positive
BAL viral screening, thus suggesting a high negative predictive
value. However, this value should be balanced with the relatively
low prevalence of each individual respiratory virus in BAL fluid
specimens and the possible technical issues related to naso-
pharyngeal and pharyngeal swabbing that could negatively af-
fect the recovery rate. Our population was first selected on the
basis of the need to perform a BAL procedure; for this reason,
we caution that a lower respiratory tract viral infection in lung
transplant recipients cannot be definitely ruled out by a naso-
pharyngeal swab. Yet this could be a reasonable initial screen-
ing strategy that needs to be confirmed in further studies and
individually for each type of virus.
In conclusion, our study demonstrates that there is a tem-
poral relationship in lung transplant recipients between the
emergence of acute respiratory symptoms and positive respi-
ratory viral nucleic acid detection in BAL fluid specimens.
When detected only in the upper respiratory tract, viral infec-
tions are less likely to be associated with respiratory symptoms
and graft dysfunction. We also provide solid evidence suggesting
that respiratory viruses per se do not promote acute graft re-
jection, at least during the acute phase of infection, but that
they do worsen graft function recovery when simultaneously
present with acute rejection.
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